Roth Capital Initiates Coverage on Capricor Therapeutics (NASDAQ:CAPR)
Equities researchers at Roth Capital started coverage on shares of Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) in a report issued on Tuesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $31.00 price target on the biotechnology company’s stock. Roth Capital’s price objective points to a potential upside of 178.78% from the company’s […]
Equities researchers at Roth Capital started coverage on shares of Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) in a report issued on Tuesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $31.00 price target on the biotechnology company’s stock. Roth Capital’s price objective points to a potential upside of 178.78% from the company’s […]
